Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04229160 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Noninvasive 3D Mapping in Persistent Atrial Fibrillation, to Describe Modifications of the Arrhythmogenic Substrate After Pulmonary Vein Isolation and Identify Potential Predicting Factors of Ablation Success

Study acronym: CRYOVEST
StatusCompleted
PhaseNot applicable
Started2020-06-09
View on ClinicalTrials.gov ↗

Amendment history

2026-09-26
critical
Trial completed
Final enrollment: 40 participants (planned 50)
Primary completion pushed: 2025-06-24 → 2026-06-17
2025-09-10
notable
Recruiting→Active, Not Recruiting Study Identification, Study Status, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Primary completion dateestimated 2023-06→confirmed 2025-06-24
Completion date2023-06→2026-06-24
Study sitesdetails revised at 4 of 4 sites
2020-06-24
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2023-03→2023-06
Completion date2023-03→2023-06
Start dateestimated 2020-03→confirmed 2020-06-09
Study sitesdetails revised at 4 of 4 sites
2020-01-10
minor
Original filing
Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. It is a major cause of ischemic stroke and heart failure. Intravascular cardiac ablation of the left atrium by catheter delivery is an efficient treatment to restore sinus rhythm. AF ablation is a class IIa treatment for patients with symptomatic persistent AF refractory or intolerant to antiarrhythmic medication. There are still many debates considering the ablation strategy. The pulmonary veins remain the cornerstone of AF ablation therapy, even in persistent AF. There is a large electrical remodeling occurring in the left atrium between paroxysmal AF, early persistent AF and long-standing persistent AF. However, no multicentric and randomized study has demonstrated so far the interest of targeting other left atrial substrate, such as rotors or focal sources. Our study aims to describe with a noninvasive mapping system the arrhythmogenic substrate of persistent AF \> 6 months pre- and post-cardioversion, and after pulmonary vein isolation.
Trial Details
NCT Number NCT04229160
Lead Sponsor University Hospital, Rouen
Conditions Atrial Fibrillation, Persistent
Enrollment 40 participants
Start Date 2020-06-09
Primary Completion 2026-06-17 (estimated)
Study Completion 2026-06-17 (estimated)
Updated on ClinicalTrials.gov 2026-09-25